DE60012554T2 - Beta-agonisten zur behandlung der endometriose bzw. unfruchtbarkeit oder steigerung der fruchtbarkeit - Google Patents

Beta-agonisten zur behandlung der endometriose bzw. unfruchtbarkeit oder steigerung der fruchtbarkeit Download PDF

Info

Publication number
DE60012554T2
DE60012554T2 DE60012554T DE60012554T DE60012554T2 DE 60012554 T2 DE60012554 T2 DE 60012554T2 DE 60012554 T DE60012554 T DE 60012554T DE 60012554 T DE60012554 T DE 60012554T DE 60012554 T2 DE60012554 T2 DE 60012554T2
Authority
DE
Germany
Prior art keywords
endometriosis
terbutaline
uterine
adrenergic
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60012554T
Other languages
German (de)
English (en)
Other versions
DE60012554D1 (de
Inventor
J. William BOLOGNA
Dominique De Ziegler
L. Howard LEVINE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia Laboratories Bermuda Ltd
Original Assignee
Columbia Laboratories Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Laboratories Bermuda Ltd filed Critical Columbia Laboratories Bermuda Ltd
Publication of DE60012554D1 publication Critical patent/DE60012554D1/de
Application granted granted Critical
Publication of DE60012554T2 publication Critical patent/DE60012554T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE60012554T 1999-10-05 2000-10-04 Beta-agonisten zur behandlung der endometriose bzw. unfruchtbarkeit oder steigerung der fruchtbarkeit Expired - Lifetime DE60012554T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US15775499P 1999-10-05 1999-10-05
US157754P 1999-10-05
US66838400A 2000-09-25 2000-09-25
US668384 2000-09-25
PCT/EP2000/009708 WO2001024788A2 (en) 1999-10-05 2000-10-04 Treating endometriosis or infertility, or improving fertility

Publications (2)

Publication Number Publication Date
DE60012554D1 DE60012554D1 (de) 2004-09-02
DE60012554T2 true DE60012554T2 (de) 2005-11-24

Family

ID=26854456

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60012554T Expired - Lifetime DE60012554T2 (de) 1999-10-05 2000-10-04 Beta-agonisten zur behandlung der endometriose bzw. unfruchtbarkeit oder steigerung der fruchtbarkeit

Country Status (28)

Country Link
EP (1) EP1220667B1 (cg-RX-API-DMAC7.html)
JP (2) JP2003510354A (cg-RX-API-DMAC7.html)
KR (1) KR100738724B1 (cg-RX-API-DMAC7.html)
CN (1) CN1218694C (cg-RX-API-DMAC7.html)
AR (1) AR028487A1 (cg-RX-API-DMAC7.html)
AT (1) ATE271860T1 (cg-RX-API-DMAC7.html)
AU (1) AU780736B2 (cg-RX-API-DMAC7.html)
BR (1) BR0014548A (cg-RX-API-DMAC7.html)
CA (1) CA2385974C (cg-RX-API-DMAC7.html)
CO (1) CO5251423A1 (cg-RX-API-DMAC7.html)
DE (1) DE60012554T2 (cg-RX-API-DMAC7.html)
DK (1) DK1220667T3 (cg-RX-API-DMAC7.html)
ES (1) ES2223581T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20043313B (cg-RX-API-DMAC7.html)
HK (1) HK1044120B (cg-RX-API-DMAC7.html)
HU (1) HU225990B1 (cg-RX-API-DMAC7.html)
IL (2) IL148784A0 (cg-RX-API-DMAC7.html)
MA (1) MA25501A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA02003453A (cg-RX-API-DMAC7.html)
MY (1) MY129518A (cg-RX-API-DMAC7.html)
NO (1) NO329663B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ518429A (cg-RX-API-DMAC7.html)
PE (1) PE20010742A1 (cg-RX-API-DMAC7.html)
PT (1) PT1220667E (cg-RX-API-DMAC7.html)
TR (1) TR200200899T2 (cg-RX-API-DMAC7.html)
TW (1) TWI280877B (cg-RX-API-DMAC7.html)
UA (1) UA74168C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001024788A2 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8425892B2 (en) 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
CN101327326A (zh) * 2001-10-29 2008-12-24 哥伦比亚实验室(百慕大群岛)有限公司 阴道给药治疗骨盆痛和不孕症的抗节律障碍剂
ES2237298B1 (es) 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
EP1872775A1 (en) 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
MX2012010327A (es) * 2010-03-22 2012-11-16 Repros Therapeutics Inc Composiciones y metodos para la administracion no toxica de antiprogestinas.
KR101010031B1 (ko) * 2010-12-08 2011-01-21 류상범 흡수식 냉온수기용 엘리미네이터
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
CN116172995A (zh) * 2023-01-17 2023-05-30 浙江大学医学院附属妇产科医院 一种沙丁胺醇在制备治疗子宫内膜异位症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241087A (en) * 1979-04-02 1980-12-23 William H. Rorer, Inc. Dysmenorrhea treatment
NZ232801A (en) * 1989-03-07 1992-01-29 Adeza Biomedical Corp Diagnostic test for endometriosis
JP2602456B2 (ja) * 1990-04-12 1997-04-23 雪印乳業株式会社 子宮内膜症治療剤
IT1251114B (it) * 1991-07-26 1995-05-04 Farcon Ag Forme farmaceutiche antivirali per applicazione vaginale
DE69819748T2 (de) * 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen

Also Published As

Publication number Publication date
KR100738724B1 (ko) 2007-07-12
HU225990B1 (en) 2008-02-28
IL148784A0 (en) 2002-09-12
EP1220667B1 (en) 2004-07-28
CA2385974C (en) 2010-01-26
NO20021591D0 (no) 2002-04-04
CN1377264A (zh) 2002-10-30
HK1044120A1 (en) 2002-10-11
TR200200899T2 (tr) 2002-07-22
UA74168C2 (uk) 2005-11-15
MXPA02003453A (es) 2002-08-20
MY129518A (en) 2007-04-30
NZ518429A (en) 2004-02-27
WO2001024788A2 (en) 2001-04-12
NO20021591L (no) 2002-05-28
KR20020062285A (ko) 2002-07-25
CO5251423A1 (es) 2003-02-28
HUP0203050A3 (en) 2006-02-28
MA25501A1 (fr) 2002-07-01
AR028487A1 (es) 2003-05-14
ES2223581T3 (es) 2005-03-01
WO2001024788A3 (en) 2001-12-06
DE60012554D1 (de) 2004-09-02
HUP0203050A2 (hu) 2003-02-28
IL148784A (en) 2006-12-31
JP2010018639A (ja) 2010-01-28
DK1220667T3 (da) 2004-12-06
NO329663B1 (no) 2010-11-29
AU780736B2 (en) 2005-04-14
AU7525000A (en) 2001-05-10
CA2385974A1 (en) 2001-04-12
PE20010742A1 (es) 2001-07-19
CN1218694C (zh) 2005-09-14
EP1220667A2 (en) 2002-07-10
GEP20043313B (en) 2004-03-10
PT1220667E (pt) 2004-11-30
HK1044120B (en) 2004-12-17
ATE271860T1 (de) 2004-08-15
JP2003510354A (ja) 2003-03-18
TWI280877B (en) 2007-05-11
BR0014548A (pt) 2002-06-04

Similar Documents

Publication Publication Date Title
DE69819748T2 (de) Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
DE3780222T2 (de) Pharmazeutische zusammensetzung mit kontrollierter wirkstofffreisetzung.
EP2445491B1 (de) Pharmazeutische zusammensetzung zur notfallempfängnisverhütung
JP2010018639A (ja) 子宮内膜炎または不妊症の処置および妊孕性の改善
CH638987A5 (de) Langsam und gleichmaessig wirkstoffe freisetzende pharmazeutische zubereitung.
CN101917848B (zh) 用于治疗子宫收缩过强病症的s-烷基异硫脲衍生物
WO2014079840A1 (de) Verwendung und anwendungsregime einer pharmazeutischen zusammensetzung enthaltend levonorgestrel und einen cox-inhibitor zur bedarfsweisen ("on-demand") kontrazeption
US6818672B1 (en) Treating endometriosis or infertility, or improving fertility
DE10393805T5 (de) Pharmazeutische Formulierungen, die ß-2-Adrenorezeptor-Agonisten und Xantine enthalten
DE202021004490U1 (de) Verwendung von kombinierten oralen Kontrazeptiva, enthaltend Nomegestrolacetat und Estradiol
EP1356806A1 (en) A pharmaceutical composition for treating dysmenorrhea and premature labor
HK1055896A (en) A pharmaceutical composition for treating dysmenorrhea and premature labor
HK1025055B (en) A pharmaceutical composition for treating dysmenorrhea and premature labor
WO2009015766A1 (de) Einphasisches pharmazeutisches kombinationspräparat (dienogest und ethinylestradiol) zur oralen therapie der regulierung des blutdruckes
EP2020235A1 (de) einphasisches pharmazeutisches kombinationspräparat (dienogest und ethinylestradiol) zur oralen therapie der regulierung des blutdruckes
DD295345B5 (de) Verfahren zur Herstellung einer Verapamil-Arzneiform mit gleichmaessig verzoegerter Wirkstofffreisetzung

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1220667

Country of ref document: EP

Representative=s name: TERGAU & WALKENHORST PATENT- UND RECHTSANWAELTE, 9